Trial Profile
Efficacy and safety of ponatinib in patients with advanced chronic myeloid leukaemia with T315I mutation and relapsed/refractory Philadelphia chromosome positive acute lymphoblastic leukaemia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2014
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 27 Jun 2014 New trial record